The Institut team publishes a new scientific article in the prestigious Clinical Ophthalmology

The study, signed by the Director of the Institut, Dr. Monés, and Dr. Badal and Marc Biarnés, proposes an innovative approach in the treatment of retinal angiomatous proliferation. This pathology, a subtype of age-related macular degeneration (AMD), leads to serious damage with a high risk of retinal pigment epithelial detachments during treatment of the disease. In the cases when tearing of the epithelium occurs, the patient suffers irreversible loss of visual acuity.

In the article, which was published in the June edition ofClinical Ophthalmology, the researchers of the Institut de la Màcula propose a bimonthly treatment with a half dose of the intravitreal injections used to cure other AMD subtypes. In this way, the final dose applied to the patient is the same as in other protocols but the risk of tearing the pigment epithelium is minimised, providing the best guarantees for maintaining the patient’s visual acuity.

Dr. Badal says “this study highlights the possibility of modifying the current protocol for treating retinal angiomatous proliferation by maintaining the dose of the drug administered and reducing the risk of damaging the epithelium irreparably”.

For the original article published by Clinical Ophthalmology click here.